2026 ICD-10-CM Diagnosis Code T42.0X6AUnderdosing of hydantoin derivatives, initial encounter
T42.0X6A is a billable ICD-10-CM diagnosis code for underdosing of hydantoin derivatives, initial encounter. The 7th character A marks it as an initial encounter code, used while the patient is receiving active treatment. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026). The code is not accepted as a principal diagnosis by the Medicare Code Editor. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Underdosing of drugs and medicaments, initial encounter.
Code Identity
Code Classification
Code EditsBilling
Medicare Code Editor checks that affect claim validity for T42.0X6A.
Coding GuidelinesGuidance
Underdosing refers to taking less of a medication than is prescribed by a provider or a manufacturer's instruction. Codes for underdosing should never be assigned as principal or first-listed codes. If a patient has a relapse or exacerbation of the medical condition for which the drug is prescribed because of the reduction in dose, then the medical condition itself should be coded.
The appropriate 7th character is to be added to each code from block Poisoning by, adverse effect of and underdosing of antiepileptic, sedative- hypnotic and antiparkinsonism drugs (T42). Use the following options for the applicable episode of care:
- A - initial encounter
- D - subsequent encounter
- S - sequela
Source: ICD-10-CM Official Guidelines for Coding and Reporting, FY 2026, published by CMS and the National Center for Health Statistics.
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Mephenytoin
an anticonvulsant effective in tonic-clonic epilepsy (epilepsy, tonic-clonic). it may cause blood dyscrasias.Phenytoin
an anticonvulsant that is used to treat a wide variety of seizures. it is also an anti-arrhythmic and a muscle relaxant. the mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. the mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs.
Table of Drugs and ChemicalsClinical
Substances in the Table of Drugs and Chemicals that reference this code family. Always confirm in the Tabular List before coding.
| Substance | Accidental | Self-harm | Assault | Undetermined | Adverse Effect | Underdosing |
|---|---|---|---|---|---|---|
| Albutoin | T42.0X1 | T42.0X2 | T42.0X3 | T42.0X4 | T42.0X5 | T42.0X6 |
| Dilantin | T42.0X1 | T42.0X2 | T42.0X3 | T42.0X4 | T42.0X5 | T42.0X6 |
| Diphenylhydantoin | T42.0X1 | T42.0X2 | T42.0X3 | T42.0X4 | T42.0X5 | T42.0X6 |
| Epanutin | T42.0X1 | T42.0X2 | T42.0X3 | T42.0X4 | T42.0X5 | T42.0X6 |
| Ethotoin | T42.0X1 | T42.0X2 | T42.0X3 | T42.0X4 | T42.0X5 | T42.0X6 |
| Hydantoin derivative NEC | T42.0X1 | T42.0X2 | T42.0X3 | T42.0X4 | T42.0X5 | T42.0X6 |
| Mephenytoin | T42.0X1 | T42.0X2 | T42.0X3 | T42.0X4 | T42.0X5 | T42.0X6 |
| Mephenytoin::with phenobarbital | T42.0X1 | T42.0X2 | T42.0X3 | T42.0X4 | T42.0X5 | T42.0X6 |
| Metetoin | T42.0X1 | T42.0X2 | T42.0X3 | T42.0X4 | T42.0X5 | T42.0X6 |
| Methetoin | T42.0X1 | T42.0X2 | T42.0X3 | T42.0X4 | T42.0X5 | T42.0X6 |
| Methoin | T42.0X1 | T42.0X2 | T42.0X3 | T42.0X4 | T42.0X5 | T42.0X6 |
| Phenantoin | T42.0X1 | T42.0X2 | T42.0X3 | T42.0X4 | T42.0X5 | T42.0X6 |
| Phenytoin | T42.0X1 | T42.0X2 | T42.0X3 | T42.0X4 | T42.0X5 | T42.0X6 |
| Phenytoin::with Phenobarbital | T42.0X1 | T42.0X2 | T42.0X3 | T42.0X4 | T42.0X5 | T42.0X6 |
Patient EducationClinical
Medication Errors
Medicines treat infectious diseases, prevent problems from chronic diseases, and ease pain. But medicines can also cause harmful reactions if not used correctly. Errors can happen in the hospital, at the health care provider's office, at the pharmacy, or at home. You can help prevent errors by:
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert T42.0X6A to ICD-9-CMHistory
Code HistoryHistory
Questions About T42.0X6AOverview
Is T42.0X6A (Underdosing of hydantoin derivatives) a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report underdosing of hydantoin derivatives, initial encounter on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
What does the 7th character A in T42.0X6A mean?
The final character A marks the initial encounter: use it while the patient is receiving active treatment for underdosing of hydantoin derivatives, such as an emergency visit or first evaluation.
Can T42.0X6A be a principal diagnosis?
No. The Medicare Code Editor rejects this code as a principal diagnosis because underdosing of hydantoin derivatives, initial encounter describes a circumstance that influences health status rather than a current illness. Report it as a secondary diagnosis.
Footnotes
[1] Not chronic - A diagnosis code that does not fit the criteria for chronic condition (duration, ongoing medical treatment, and limitations) is considered not chronic. Some codes designated as not chronic are acute conditions. Other diagnosis codes that indicate a possible chronic condition, but for which the duration of the illness is not specified in the code description (i.e., we do not know the condition has lasted 12 months or longer) also are considered not chronic.
